Immunology and inflammation
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- KAROLINSKA INSTITUTET
Sweden's premier medical university driving cancer, neuroscience, and personalized medicine research with 292 H2020 projects and EUR 200M in funding.
“Inflammation appears in 5 recent-period projects, with earlier work on mucosal immunity (EMI-TB), innate lymphoid cells (GutILC3), and tissue regeneration (RETHRIM).”
SE292 projects - VIB VZW
Belgium's leading life sciences research institute, spanning immunology, neuroscience, plant biology, and structural biology with strong EU project leadership.
“Extensive work on dendritic cells, Kupffer cells, macrophages, tissue-resident immune cells, and inflammatory diseases including asthma, allergy, and IBD (projects: KCs and Gut Antigens, Tissue-Tregs, ENVIROIMMUNE, PIBD-SETQuality, FMF-Dia).”
PrimaryBE126 projects - UNIVERSITE DE LAUSANNE
Swiss research university excelling in evolutionary biology, immunology, and metabolic disease, with exceptional ERC and MSCA grant density.
“Projects spanning innate immunity (STRAVIR on IL-33 in anti-viral immunity), vaccine development (EHVA, TBVAC2020, OptiMalVax), and immune-mediated cross-priming in cancer (PROCROP).”
PrimaryCH102 projects